Bacillus Calmette–Guérin (BCG) was repurposed as intravesical immunotherapy for bladder cancer following its success as a tuberculosis vaccine. Its anti-tumour activity is multifaceted. Directly, BCG induces apoptosis, necrosis and oxidative stress through caspase activation, tumour necrosis factor–alpha (TNF-α) signaling and production of nitric
oxide and reactive oxygen species (ROS), damaging tumour DNA and proteins.
Animal models are a fundamental part of preclinical scientific research in the development of new therapies, including drugs and gene therapies. For such purposes, it is crucial to have an animal model that aligns with the study being conducted.
Read More...
Breast cancer is the most common malignant tumor and the main cause of death in women worldwide. With increased knowledge regarding tumor escape mechanisms and advances in immunology, many new antitumor strategies make immunotherapy a promising approach for the treatment of this disease.
Read More...
ConvitVax is a personalized vaccine for the treatment of breast cancer, composed of autologous tumor cells, bacillus Calmette-Guérin (BCG) and low concentrations of formalin…
Read More...
New Study on Breast Cancer Jacinto Convit World Organization (JCWO) is pleased to announce the publication of their latest work[…]
Read More...